Citicoline is a nucleic acid derivatives, Geiger found that citicoline can restore brain injury in the animal experiments in 1956. Kennedy study confirmed that citicoline can make brain injury recovery in 1957. Takeda pharmaceutical company in Japan developed and produced it in 1961. It was registered in China in 1988, and is currently the best-selling drug among clinical brain diseases. It plays an important role in the synthesis of lecithin, by promoting the synthesis of lecithin and improving brain function. Experiments show that citicoline can enhance the levels of norepinephrine and dopamine in the central nervous system, thereby it can treat cerebrovascular disease, traumatic brain injury and cognitive impairment caused by various reasons, and there are no obvious side effects.
Citicoline sodium can enhance the function of brain stem reticular formation, especially the ascending reticular activating system associated with human consciousness; enhance the function of the pyramidal system; inhibit the function of the external system of the cone, and promotes the recovery of the function of the system. For the treatment of sequelae of traumatic brain injury and cerebral vascular accident caused by the nervous system, it can also be used in the treatment of Parkinson's disease, senile dementia has a certain effect; for the treatment of cardiovascular and cerebrovascular diseases; it also have a certain effect for anti-aging, improving learning and memory.
